BioNTech SE

Welcome to the BioNTech fourth quarter and year end update call. I would now like to hand the call over to Michael Horowitz, investor relations and strategy.

Please go ahead, Michael. Good morning and afternoon.

Thank you for joining us today for BioNTech's fourth quarter and full year 2022 earnings call. As a brief reminder, the slides that accompany this call and the fourth quarter and full year 2022 press release was issued this morning can be found in the investor section of our website. As outlined on slide two, you can see our forward-looking statements disclaimer. Additional information about these statements and other risks are described in our filings made with the U.S. Securities and Exchange Commission, including our most recent annual report on Form 20S. Forward-looking statements on the call are subject to substantial risks and uncertainties, speak only as of the call's original date, and we undertake no obligation to update or revise any of the statements. On slides three and four, you can see detailed safety information regarding our COVID-19 vaccine. And on slide five, you can find the agenda for today's call. Today, I am joined by the following members of Biontech's management team. Our CEO and co-founder, Ullur Zahin, Oslobun Tureci, our chief medical officer and co-founder, Jens Horstein, our chief financial officer, and Ryan Richardson, our chief strategy officer. I would like to turn the call over to Ullur Zahin.